After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.
News & Analysis: Iovance Biotherapeutics, Inc.
The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.
IOVA earnings call for the period ending March 31, 2020.
The worst may be yet to come for the stock market, but these biopharma companies have promising potential.
Rumors of a buyout swirled around the biopharma.
IOVA earnings call for the period ending December 31, 2019.
Bloomberg reports that the company has been toying with the idea of a sale.
Results from an experimental combination therapy were impressive, but they might not be impressive enough.
These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.
The company announced a string of deals over the weekend that failed to spark investors' optimism.